🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Krsnaa Diagnostics Limited KRSNAA NSEPHARMA

Healthcare · Diagnostics & Research · India
https://krsnaadiagnostics.com
Company Profile ↓
₹515.00
-35.74% 1Y
Mkt Cap₹1,670.59 Cr
P/E17.37
P/B1.77
Div. Yield0.36%
52W High₹863.00
52W Low₹512.80
Book Value₹302.21
EPS (TTM)₹29.65

Company Overview

Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well as tele-radiology and tele-pathology services. The company was incorporated in 2010 and is based in Pune, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 17.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 17.4, below the sector median of 36.4.

Recent Developments

  • Mar 2026 Revenue of ₹772.77 Cr (+7.8% YoY); net profit ₹101.43 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.1%, earnings -19.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR 17.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.63%
1 Year:22.10%

Compounded Profit Growth

5 Years:17.76%
1 Year:-19.40%

Stock Price Performance

1 Year:-35.74%
6 Months:-14.00%
3 Months:-4.58%
1 Month:-4.83%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 1% of range
₹512.80 ₹863.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.36 · Neutral
Price Performance
1M-4.83%
3M-4.58%
6M-14.00%
1Y-35.74%
Valuation vs Sector

P/E of 17.37 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.6% over 5 years.
  • Profit CAGR of 17.8% over 5 years.

CONS

  • Trading 40.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
17.37
Industry PE
36.43
Forward P/E
11.12
PEG Ratio
-
Book Value
₹302.21
Price to Book
1.77
P/S
2.06
EV/EBITDA
8.10
Dividend Yield
0.36%

Growth (CAGR)

Revenue 5Y
16.63%
Profit 5Y
17.76%
Revenue (YoY)
22.10%
Earnings (YoY)
-19.40%

Profitability & Returns

ROCE
10.51%
ROE
10.35%
ROA
5.56%
Profit Margin
11.58%
Op Margin
12.75%
Gross Margin
78.39%
EPS (Latest Qtr)
₹5.04
EPS (TTM)
₹29.65

Balance Sheet & Liquidity

Debt/Equity
0.55
Quick Ratio
2.59
Current Ratio
2.68
Debt
₹534.32 Cr
Total Assets
₹1,823.72 Cr
Current Assets
₹738.34 Cr
Working Capital
₹463.14 Cr

Ownership

Promoter Holding
45.69%
Chg in Prom Hold
-
FII / Inst Holding
13.52%
Chg in FII Hold
0.06%

Financial Snapshot

Enterprise Value
₹1,670.59 Cr
Total Revenue (TTM)
₹841.28 Cr
EBITDA
₹241.17 Cr
Free Cash Flow
₹-76.16 Cr
Operating Cash Flow
₹143.10 Cr
Shares Outstanding
₹3.24 Cr
Gross Margin
78.39%
Payout Ratio
9.27%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KRSNAA Krsnaa Diagnostics Limited NSEPHARMA 515.00 17.37 ₹1,670.59 Cr 0.36% 10.51% 10.35% 16.63% 17.76%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 133.00 Cr140.00 Cr155.00 Cr158.00 Cr166.00 Cr170.00 Cr186.00 Cr175.00 Cr186.08 Cr192.98 Cr205.99 Cr181.20 Cr192.60 Cr235.53 Cr
Cost of Revenue --------58.95 Cr62.79 Cr65.14 Cr54.14 Cr58.68 Cr90.77 Cr
Gross Profit --------127.12 Cr130.19 Cr140.85 Cr127.06 Cr133.93 Cr144.76 Cr
Operating Expenses 99.00 Cr108.00 Cr124.00 Cr121.00 Cr123.00 Cr128.00 Cr137.00 Cr129.00 Cr96.09 Cr100.42 Cr105.28 Cr103.28 Cr101.64 Cr114.74 Cr
Operating Income 19.00 Cr15.00 Cr13.00 Cr16.00 Cr26.00 Cr22.00 Cr27.00 Cr22.00 Cr31.03 Cr29.76 Cr35.57 Cr23.79 Cr32.29 Cr30.02 Cr
EBITDA 34.00 Cr31.00 Cr32.00 Cr37.00 Cr44.00 Cr43.00 Cr49.00 Cr45.00 Cr57.37 Cr55.35 Cr63.34 Cr50.13 Cr86.37 Cr65.22 Cr
Interest Expense 2.00 Cr2.00 Cr3.00 Cr4.00 Cr7.00 Cr5.00 Cr6.00 Cr6.00 Cr6.81 Cr6.30 Cr8.19 Cr7.79 Cr12.08 Cr14.83 Cr
Pretax Income 24.00 Cr18.00 Cr13.00 Cr16.00 Cr23.00 Cr23.00 Cr25.00 Cr25.00 Cr28.61 Cr27.42 Cr31.56 Cr19.68 Cr51.70 Cr22.44 Cr
Tax Provision 4.80 Cr3.24 Cr2.86 Cr3.04 Cr3.91 Cr5.29 Cr5.75 Cr6.00 Cr7.93 Cr6.90 Cr7.62 Cr4.44 Cr9.98 Cr5.88 Cr
Net Income 19.00 Cr15.00 Cr10.00 Cr13.00 Cr19.00 Cr18.00 Cr20.00 Cr19.00 Cr20.68 Cr20.52 Cr23.95 Cr15.25 Cr41.72 Cr16.55 Cr
Diluted EPS 6.034.663.344.025.805.556.076.016.286.257.254.6612.705.04

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 39.00 Cr61.00 Cr-487.12 Cr619.63 Cr717.16 Cr772.77 Cr
Cost of Revenue ---155.39 Cr206.51 Cr229.94 Cr240.75 Cr
Gross Profit ---331.74 Cr413.12 Cr487.22 Cr532.02 Cr
Operating Expenses 30.00 Cr42.00 Cr-262.50 Cr343.37 Cr385.38 Cr410.54 Cr
Operating Income 3.00 Cr7.00 Cr-69.24 Cr69.75 Cr101.84 Cr121.48 Cr
EBITDA 9.00 Cr19.00 Cr-140.42 Cr158.64 Cr212.77 Cr253.22 Cr
Interest Expense 9.00 Cr9.00 Cr-6.43 Cr14.09 Cr21.76 Cr32.39 Cr
Pretax Income -3.00 Cr0-80.20 Cr70.01 Cr102.69 Cr130.37 Cr
Tax Provision -1.47 Cr0-18.09 Cr13.17 Cr25.08 Cr28.94 Cr
Net Income -5.00 Cr-0-62.11 Cr56.84 Cr77.61 Cr101.43 Cr
Diluted EPS -9.53-0.14-19.2917.3123.5630.88

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 186.00 Cr192.00 Cr-909.89 Cr1,171.91 Cr1,281.60 Cr1,823.72 Cr
Current Assets ---222.91 Cr421.19 Cr414.47 Cr738.34 Cr
Cash & Equivalents ---22.72 Cr2.38 Cr3.85 Cr30.22 Cr
Inventory ---25.07 Cr35.81 Cr29.48 Cr26.66 Cr
Receivables ---73.10 Cr176.29 Cr277.75 Cr295.51 Cr
Total Liabilities ---171.16 Cr362.11 Cr398.82 Cr843.33 Cr
Current Liabilities ---99.19 Cr281.47 Cr305.39 Cr275.20 Cr
Long Term Debt ---11.00 Cr5.50 Cr18.50 Cr437.14 Cr
Total Debt 131.00 Cr102.00 Cr-32.48 Cr159.79 Cr203.53 Cr534.32 Cr
Total Equity 11.00 Cr11.00 Cr-738.74 Cr809.80 Cr882.77 Cr980.39 Cr
Shares Outstanding ---3.14 Cr3.23 Cr3.23 Cr3.24 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -23.00 Cr64.00 Cr-76.30 Cr24.34 Cr87.33 Cr143.10 Cr
Investing Cash Flow -47.00 Cr-54.00 Cr--108.89 Cr-128.88 Cr-99.61 Cr-395.99 Cr
Financing Cash Flow 105.00 Cr-41.00 Cr--33.15 Cr84.19 Cr13.75 Cr279.26 Cr
Capital Expenditure -46.00 Cr-54.00 Cr--141.36 Cr-193.89 Cr-126.63 Cr-219.26 Cr
Free Cash Flow -69.00 Cr10.00 Cr--65.06 Cr-169.54 Cr-39.30 Cr-76.16 Cr
Net Change in Cash 36.00 Cr-31.00 Cr--65.73 Cr-20.34 Cr1.47 Cr26.38 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---68.1%66.7%67.9%68.8%
Operating Margin % 7.7%11.5%-14.2%11.3%14.2%15.7%
Net Margin % -12.8%-0.0%-12.8%9.2%10.8%13.1%
ROE % -45.5%-0.0%-8.4%7.0%8.8%10.3%
ROCE % ---8.5%7.8%10.4%7.8%

Shareholding Pattern

Insiders
45.69%
Institutions
13.52%
Public Float
24.89%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KRSNAA

Google News Mon, 19 Oct 2026

Krsnaa Diagnostics Dividend 2026: ₹2.00, Record Date 18 Sep - INDmoney

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTFBsSVBPeTBqRk13bUFUb2JCOUlpcU41RFBGS0Z3cW9lc3lPSXhrZFpBclRNaVBVeGhBd2FkSUlfZXR4N3VPSm9WbmkwRFhhbkl4QU1XeHBDaUZhMmhmSGw4bktmZTN4LUtLMzRlS3d1dm9venJldlpNcWtQenM?oc=5" target="_blank">…

Google News ue, 20 Oct 2026

Krsnaa Diagnostics (BSE:543328) - Stock Analysis - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNT0Z6OExXOV9McnlDclhhQUNVUzQ3eFFkbmFoRGZkdWpLcUlLOXNHREZZNEx4ay16ZUlTeUd6cDNxcVBONVlKOEE5emVNT1dQWXExcDFqYmhXZU15Um1OSXgwOVZUWEk5R0JMd1dTNFFOQmh5UFhmeUNNTEF5ZnN3ZUpidTBEQQ?oc=5" t…

Google News Sat, 27 Jun 2026

KRSNAA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE96eTdUMnkwM1NuUDlrR1d0c09BSU9yMnpubG1LSnN4VERrdGZ5OXkyTUhURDlxcmpqbkxnMHJYNndhQmNUTkZiem82ZWE5emczYmZySVRXaW9aY2pFTUpkZzk1NWhrc0lVUVFvRFE2V3VfaU1vT09jbQ?oc=5" target="_blank">KRSNA…

Google News hu, 22 Oct 2026

Krsnaa Diagnostics 52 Week Low Streak: Price, Valuation - Univest

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPNGtXRVJETURCNTlRNTZaaEJtU0lFTWlXd3NiWU0xcnptODEtNTVTODFOd1dBdnV1QzJpU1ZRWVdvM04xeHlKVHc3eGNQRVlNTS1QUVhEak5OV2tZcVhkaWY5SHc2S29lTXJCY3h0dnZtYkxHMHB6M0YtejJBWktLU1NDTXNGd3pPTHVlZ1…

Google News Sat, 29 Aug 2026

Krsnaa Diagnostics Ltd. Stock News - Value Research

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxObUstV3FFVC1kT2VfaVpTQWZWTHFWdnhWdUZHMHhjTWprNHRYQlpTc0l6aEx4akZsdHh6ZUZyWHl0TzJqNF84aWpLVWF4MUtRMS1CVmc3dmJRWnAwRTBscnVJME80ZE5QYlJ5dnlyVEIyemJGcU5JamRvRFN6d3JPLW1qU0w?oc=5" targ…

Google News Mon, 28 Sep 2026

Krsnaa Diagnostics to sell diagnostic equipment worth up to ₹120 crore - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPUlpHU3pDLXhLWEJ0aGhNMUFKZThxZWFQazBWYkJRQk1zTHlLTVZXZ0p4Ti00N0d1MC1aYkZBb3l4ZjJTR1FqWGRPOXJHellhamh1NWpfcjQxVXVwNWlkbzFOdFdqVjl1MUx2NHlySHJHOFFMNDB6QnpzMnY3SzhGdHJVYTNRcG81V0EtQW…

KRSNAA — Frequently Asked Questions

What is the current share price of Krsnaa Diagnostics Limited (KRSNAA)?

As of 2026-10-23 04:58 IST, Krsnaa Diagnostics Limited (KRSNAA) trades at ₹515.00 on NSE. Its 52-week range is ₹512.80 to ₹863.00.

What is the market capitalisation of KRSNAA?

Krsnaa Diagnostics Limited (KRSNAA) has a market capitalisation of ₹1,670.59 Cr on NSE.

What is the P/E ratio of KRSNAA?

KRSNAA trades at a trailing price-to-earnings (P/E) ratio of 17.37. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 1.77.

Does KRSNAA pay a dividend?

Krsnaa Diagnostics Limited (KRSNAA) currently offers a dividend yield of 0.36%.

What is the return on equity (ROE) of KRSNAA?

KRSNAA has a return on equity (ROE) of 10.35%. Its return on capital employed (ROCE) is 10.51%.

Is KRSNAA a good stock to buy?

This page provides a data-driven analysis of Krsnaa Diagnostics Limited (KRSNAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space